MicroRNA-based epigenetic approach to induce fetal hemoglobin
MicroRNA-based epigenetic approach to induce fetal hemoglobin
批准号:
10212449
负责人:
Athena Starlard-Davenport
金额:
$30.53万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-13 至 2023-06-30
关键词:
3&apos Untranslated RegionsANXA5 geneAddressAdultBiological AssayBlood Cell CountCD34 geneCell ProliferationCellsChildCholesterolClinicalComplete Blood CountContinuous InfusionCytosineDNADNA DamageDNA MethylationDNA Methyltransferase InhibitorDNA Modification MethylasesDNA Sequence AlterationDataDevelopmentDifferentiation AntigensDiseaseDoseEnzymesEpigenetic ProcessErythroidErythropoiesisFDA approvedFertilityFetal HemoglobinFlow CytometryFluorescenceFunctional disorderGYPA geneGene ExpressionGene Expression ProfilingGene Expression RegulationGene SilencingGenetic TranscriptionGenomeGenotypeGlobinGoalsHematopoiesisHemoglobinopathiesHumanHypermethylationHypoxiaIn VitroIndividualInfantInfusion proceduresKnowledgeLiquid substanceMYB geneMalignant NeoplasmsMeasuresMediatingMessenger RNAMethylationMicroRNAsMolecularMonitorMusMutationOncogenesPatientsPeripheral Blood Mononuclear CellPharmaceutical PreparationsPharmacotherapyPhenotypePhysiologicalPlasmidsPlayPopulationPropidium DiiodidePublishingPumpRegulationResearchReticulocyte countRoleSeverity of illnessSickle CellSickle Cell AnemiaSpleenSubcutaneous InjectionsSwitch GenesSymptomsSystemTFRC geneTestingTherapeuticTherapeutic InterventionTissuesTransfectionTransferaseTreatment EfficacyUntranslated RNAWorkbasebench to bedsidebeta Globincancer cellchromatin modificationdrug developmentefficacy testingepigenetic silencingerythroid differentiationgamma Globinhydroxyureain vivoinnovationmethylation patternmouse modelnovelnovel therapeuticsoverexpressionpre-clinicalpreventprogenitorpromotersicklingside effectsmall moleculestem cellssubcutaneoustranscriptome sequencing
中文摘要
项目摘要
Share II的应用旨在探索控制珠蛋白基因的表观遗传机制
在红细胞生成过程中的调节。该项目的中心假设是miR-29b
逆转γ-珠蛋白向β-珠蛋白基因的转换并诱导HbF
甲基化。旨在诱导HBF表达的治疗性干预是一种有效的方法
用于改善成人和儿童镰状细胞病(SCD)的临床症状。
羟基脲是FDA批准的唯一一种已证明有效的药物,可用于诱导慢性阻塞性肺疾病患者的HBF
SCD,但DNA甲基转移酶(DNMT)抑制剂已显示出作为HBF诱导剂的前景
产生近端γ-珠蛋白启动子dna低甲基化。然而,DNMT抑制剂可以
产生偏离目标的副作用。小的非编码microRNAs(MiR)是一种具有吸引力的分子
靶向抑制γ-珠蛋白基因表达的研究表明miR-29b抑制dna
通过直接靶向DNMT3a和Dnmt3b的3‘非翻译区进行甲基化。这个
本提案的目的是测试miR-29b作为HBF诱导剂的效果。我们出版的作品
表明miR-29b对重新激活γ-珠蛋白转录和Hbf表达是重要的
靶向参与γ甲基化和基因转录的已知DNA珠蛋白抑制因子MYB
沉默。为了检验我们的中心假设,我们将实现一个特定的目标来确定
MiR-29b介导人HBB基因座DNA甲基化表观遗传改变的能力
在成人红细胞生成过程中重新激活γ-珠蛋白转录和Hbf表达。分目标A意志
用体外原液探讨miR-29b对γ-珠蛋白调节的分子作用
分离的外周血单核细胞生成红系祖细胞的培养体系
来自SCD患者。这些发现将与正常的红系祖细胞进行比较以验证
MiR-29b通过近端启动子重新激活γ-珠蛋白转录的能力
甲基化。MiR-29b介导的脱靶效应将通过DNA突变和
RNA-SEQ分析。为了确定miR-29b在逆转红系祖细胞表型中的作用
将评估在低氧条件下的镰刀运动。次级目标B将确定最佳剂量
利用临床前Townes在体内介导γ珠蛋白重新激活和HbF诱导的MIR-29b
SCD小鼠模型。这项研究强调了一种新的基于miRNA的表观遗传学方法来诱导
HBF将影响新药的发现,以扩大SCD的治疗选择。
英文摘要
Project Abstract
This SHINE II application seeks to explore epigenetic mechanisms that control globin gene
regulation during erythropoiesis. The central hypothesis of this project is that that miR-29b
reverses the γ-globin to β-globin gene switch and induces HbF via modulation of DNA
methylation. Therapeutic interventions aimed at inducing HbF expression is an effective approach
for ameliorating the clinical symptoms of sickle cell disease (SCD) in adults and children.
Hydroxyurea is the only FDA-approved drug with proven efficacy for inducing HbF in patients with
SCD, but DNA methyltransferase (DNMT) inhibitors have shown promise as HbF inducers by
producing proximal γ-globin promoter DNA hypomethylation. However, DNMT inhibitors can
produce off-target side effects. Small non-coding microRNAs (miR) are attractive molecules for
targeting repressors of γ-globin gene expression and studies show that miR-29b inhibits DNA
methylation through direct targeting of the 3’ untranslated region of DNMT3A and DNMT3B. The
objective of this proposal is to test the efficacy of miR-29b as an HbF inducer. Our published work
shows that miR-29b is important for reactivating γ-globin transcription and HbF expression by
targeting MYB, a known repressor of γ-globin involved in mediating DNA methylation and gene
silencing. To test our central hypothesis, we will accomplish one specific aim to determine the
ability of miR-29b to mediate epigenetic changes in DNA methylation in the HBB locus and
reactivate γ-globin transcription and HbF expression during adult erythropoiesis. Sub-aim A will
explore the molecular effects of miR-29b on γ-globin regulation using an in vitro primary liquid
culture system to generate erythroid progenitors from peripheral blood mononuclear cells isolated
from individuals with SCD. These findings will compare to normal erythroid progenitors to validate
the ability of miR-29b to reactivate γ-globin transcription through proximal promoter DNA
methylation. Off-target effects mediated by miR-29b will be investigated by DNA mutation and
RNA-seq analyses. To define the role of miR-29b in reversing phenotype, erythroid progenitor
sickling under hypoxic conditions will be evaluated. Sub-aim B will establish the optimal dose of
miR-29b that mediates γ-globin reactivation and HbF induction in vivo using a preclinical Townes
SCD mouse model. This research highlights a novel miRNA-based epigenetic approach to induce
HbF to impact the discovery of new drugs to expand treatment options for SCD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金